Welcome to our dedicated page for Elevation Oncolo SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevation Oncology, Inc. (ELEV) SEC filings archive provides a record of the company’s regulatory disclosures during its time as a publicly traded issuer and documents its transition to a private, wholly owned subsidiary of Concentra Biosciences, LLC. While Elevation Oncology’s common stock has been removed from listing on The Nasdaq Stock Market LLC and its registration under the Securities Exchange Act of 1934 has been terminated or suspended, its historical filings remain an important source of information about its operations, capital structure, and corporate transactions.
Investors and researchers can use Elevation Oncology’s annual reports on Form 10-K and quarterly reports on Form 10-Q (as referenced in company press releases) to review disclosures on research and development activities, general and administrative expenses, restructuring charges, and cash resources. These filings describe the company’s focus on selective cancer therapies, including its antibody-drug conjugate programs EO-3021, a Claudin 18.2 ADC, and EO-1022, a HER3 ADC in preclinical development, as discussed in its public communications.
Current reports on Form 8-K are particularly significant for understanding Elevation Oncology’s corporate evolution. A Form 8-K dated July 23, 2025 details the completion of a tender offer and merger with a subsidiary of Concentra Biosciences, through which Elevation Oncology became a wholly owned subsidiary and its common stock was converted into the right to receive cash and a contingent value right, subject to the terms of the merger agreement. The same filing explains the company’s request for Nasdaq to suspend trading and file a Form 25 to delist the shares, and notes the intention to file a Form 15 to terminate registration and suspend reporting obligations.
Subsequent regulatory steps are reflected in a Form 25 filed on July 23, 2025, which notifies the SEC of the removal of Elevation Oncology’s common stock from listing and registration on Nasdaq, and a Form 15 filed on August 4, 2025, which certifies the termination of registration of the common stock under Section 12(g) and the suspension of reporting duties under Sections 13 and 15(d). Together, these documents mark the end of Elevation Oncology’s status as a reporting company for its common stock.
On this filings page, AI-powered tools can help users quickly interpret complex regulatory language by summarizing key points from Forms 10-K, 10-Q, and 8-K, and by highlighting material events such as program discontinuations, restructuring activities, and the Concentra Biosciences acquisition. Historical insider and equity-related information referenced in merger-related disclosures, including the treatment of stock options, restricted stock units, and warrants, can also be reviewed through the underlying filings.
Elevation Oncology, Inc. Schedule 13G/A discloses that Tang Capital entities and Kevin Tang beneficially own 3,115,000 shares of common stock, representing 4.997% of the class on a fully-diluted basis. The 3,115,000 shares are currently issuable upon exercise of warrants that are immediately exercisable and expire five years from issuance. The filing states the 62,338,729-share denominator used (59,223,729 outstanding as of May 9, 2025 plus 3,115,000 warrants). Voting and dispositive power over these shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang. The filing affirms these holdings are not for control purposes.
Several Frazier Life Sciences funds and named individuals filed a Schedule 13G/A reporting that they hold no beneficial ownership of Elevation Oncology common stock. Each Reporting Person discloses 0.00 shares and 0.0% of the class, with zero sole or shared voting power and zero sole or shared dispositive power. The statement includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer.
The filing identifies the reporting entities as multiple Frazier Life Sciences partnerships and affiliated entities and names the Members as James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes. A Joint Filing Agreement is incorporated by reference. Given the reported aggregate ownership of zero, this disclosure does not change the companys ownership or voting structure.
BML Investment Partners, L.P. has filed Amendment No. 1 to Schedule 13D regarding its prior position in Elevation Oncology, Inc. (ELEV). The filing states that, as of 23 July 2025, a Merger Agreement was consummated through a tender offer by an unaffiliated “Merger Sub” that purchased all outstanding shares of Elevation Oncology common stock. Following the closing, BML Investment Partners reports 0 shares beneficially owned, representing 0 % of the class.
• Voting and dispositive power: 0 shares sole or shared.
• Source of funds: “WC” (working capital) is listed, but no new capital was deployed as the position has been exited.
• No contracts, arrangements, or legal proceedings related to the securities are disclosed, and the reporting persons confirm no criminal or civil violations within the past five years.
The amendment principally serves to formally terminate BML’s reporting obligations by documenting its complete divestiture after the successful tender offer.